Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies

Table 5 Baseline characteristics of pediatric severe sepsis patients with purpura fulminans, meningitis, or meningococcal disease

Baseline characteristics¹	No PF, MEN, or MD N = 143	PF, MEN, or MD N = 121	PF N = 87	MEN N = 50	MD N = 90
Demographics and disease severity
Age (years), mean ± SD	6.8 ± 6.3	5.6 ± 5.8	6.1 ± 5.9	5.7 ± 6.2	5.9 ± 5.8
Male (%)	46.2	53.7	50.6	52.0	55.9
Caucasian (%)	63.6	86.8	90.8	80.0	92.2
Organ dysfunctions, median; q1-q3	2.0; 1.0–3.0	2.0; 1.0–3.0	2.0; 1.0–3.0	2.0; 1.0–3.0	2.0; 1.0–3.0
First organ dysfunction to infusion (h), mean ± SD	22.3 ± 13.3	13.0 ± 10.0	13.2 ± 9.5	12.3 ± 9.1	13.0 ± 10.2
Coagulation biomarkers
Protein C level (%), median; q1-q3	38; 24–59	27; 19–38	29; 19–38	24; 16–41	26; 18–35
Platelet count, median; q1-q3	115; 58–205	88; 51–142	85; 42–122	107; 67–178	87; 53–132
APTT (s), median; q1-q3	46; 35–59	57; 41–79	57; 40–82	49; 40–70	57; 40–80
PT (s), median; q1-q3	16; 14–21	20; 15–26	20; 16–26	17; 15–23	20; 16–25
Cardiovascular and respiratory measures
Vasopressor (%)	70.8	87.4	90.0	81.6	87.5
Ventilator (%)	90.6	80.0	82.9	76.3	79.2
Cardiovascular study entry criteria (%)	82.5	93.5	97.3	90.9	96.2
Respiratory study entry criteria (%)	64.3	34.6	37.0	34.1	30.8

¹Patients with missing data were excluded from this analysis. APTT, activated partial thromboplastin time; MD, meningococcal disease; MEN, meningitis; PF, purpura fulminans; PT, prothrombin time.

ISSN: 1364-8535